Homozygous substitution of threonine 191 by proline in polymerase η causes Xeroderma pigmentosum variant

• Published in: Scientific reports 2024-01, Vol.14 (1), p.1117-1117, Article 1117
• Main Authors: Ricciardiello, Roberto, Forleo, Giulia, Cipolla, Lina, van Winckel, Geraldine, Marconi, Caterina, Nouspikel, Thierry, Halazonetis, Thanos D., Zgheib, Omar, Sabbioneda, Simone
• Format: Article
• Language: English
• Subjects: 631/208/2489/1512; 631/208/737/211; 631/337/1427/2354; 631/337/151/2354; 631/80/304; Cyclobutane pyrimidine dimers; DNA Damage; DNA-directed DNA polymerase; Frameshift mutation; Genetic counseling; Genetic screening; Homozygosity; Humanities and Social Sciences; Humans; Middle Aged; Missense mutation; multidisciplinary; Mutation; Mutation, Missense; Proline - genetics; Pyrimidine Dimers; Science; Science (multidisciplinary); Threonine; Ultraviolet Rays; Xeroderma pigmentosum; Xeroderma Pigmentosum - genetics; Xeroderma Pigmentosum - pathology
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-51120-1

DNA polymerase eta (Polη) is the only translesion synthesis polymerase capable of error-free bypass of UV-induced cyclobutane pyrimidine dimers. A deficiency in Polη function is associated with the human disease Xeroderma pigmentosum variant (XPV). We hereby report the case of a 60-year-old woman known for XPV and carrying a Polη Thr191Pro variant in homozygosity. We further characterize the variant in vitro and in vivo, providing molecular evidence that the substitution abrogates polymerase activity and results in UV sensitivity through deficient damage bypass. This is the first functional molecular characterization of a missense variant of Polη, whose reported pathogenic variants have thus far been loss of function truncation or frameshift mutations. Our work allows the upgrading of Polη Thr191Pro from ‘variant of uncertain significance’ to ‘likely pathogenic mutant’, bearing direct impact on molecular diagnosis and genetic counseling. Furthermore, we have established a robust experimental approach that will allow a precise molecular analysis of further missense mutations possibly linked to XPV. Finally, it provides insight into critical Polη residues that may be targeted to develop small molecule inhibitors for cancer therapeutics.